HRAS - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	IRAK1	interleukin 1 receptor associated kinase 1	PIP3 activates AKT signaling MyD88:MAL(TIRAP) cascade initiated on plasma membrane NOD1/2 Signaling Pathway p75NTR recruits signalling complexes p75NTR recruits signalling complexes NF-kB is activated and signals survival TAK1-dependent IKK and NF-kappa-B activation activated TAK1 mediates p38 MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Transcriptional Regulation by MECP2 Interleukin-1 signaling IRAK1 recruits IKK complex SARS-CoV-2 activates/modulates innate and adaptive immune responses TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation MyD88 dependent cascade initiated on endosome MyD88 cascade initiated on plasma membrane	Fostamatinib
Novel	IRAK2	interleukin 1 receptor associated kinase 2	MyD88:MAL(TIRAP) cascade initiated on plasma membrane NOD1/2 Signaling Pathway TAK1-dependent IKK and NF-kappa-B activation activated TAK1 mediates p38 MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 Interleukin-1 signaling IRAK2 mediated activation of TAK1 complex TRAF6-mediated induction of TAK1 complex within TLR4 complex SARS-CoV-1 activates/modulates innate immune responses SARS-CoV-2 activates/modulates innate and adaptive immune responses TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation MyD88 dependent cascade initiated on endosome IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation MyD88 cascade initiated on plasma membrane
Novel	ITGB3	integrin subunit beta 3	Platelet degranulation Elastic fibre formation PECAM1 interactions Molecules associated with elastic fibres Integrin cell surface interactions Integrin cell surface interactions TGF-beta receptor signaling activates SMADs Syndecan interactions Syndecan interactions ECM proteoglycans Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins VEGFA-VEGFR2 Pathway Signal transduction by L1 MAP2K and MAPK activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants Mechanical load activates signaling by PIEZO1 and integrins in osteocytes Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells	Abciximab Eptifibatide Antithymocyte immunoglobulin (rabbit) Levothyroxine Tirofiban Resveratrol Lefradafiban LM-609 Fradafiban Ferric maltol	Allograft rejection Glanzmann thrombasthenia
Novel	ITSN1	intersectin 1	NRAGE signals death through JNK EPHB-mediated forward signaling EPHB-mediated forward signaling G alpha (12/13) signalling events Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis CDC42 GTPase cycle RHOQ GTPase cycle RHOG GTPase cycle
Novel	KCNQ1	potassium voltage-gated channel subfamily Q member 1	Voltage gated Potassium channels Phase 3 - rapid repolarisation Phase 2 - plateau phase	Enflurane Promethazine Miconazole Bepridil Dronedarone Azimilide ICA-105665 Isavuconazole	Short QT syndrome Long QT syndrome, including: Romano-Ward syndrome; Jervell and Lange-Nielsen syndrome (JLNS) Atrial fibrillation Type II diabetes mellitus
Novel	KRAS	KRAS proto-oncogene, GTPase	Signaling by moderate kinase activity BRAF mutants Paradoxical activation of RAF signaling by kinase inactive BRAF RUNX3 regulates p14-ARF RAS processing Signaling downstream of RAS mutants Signaling by CSF3 (G-CSF) Signaling by CSF1 (M-CSF) in myeloid cells Signaling by RAS GAP mutants Signaling by RAS GTPase mutants	[(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID Farnesyl diphosphate Adagrasib Sotorasib	Acute myeloid leukemia (AML) Oral cancer Non-small cell lung cancer Multiple myeloma Cervical cancer Kaposi's sarcoma Cholangiocarcinoma Gallbladder cancer Gastric cancer Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Ovarian cancer Hepatocellular carcinoma Thyroid cancer Squamous cell carcinoma Colorectal cancer Endometrial Cancer Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome Pancreatic cancer
Novel	KRT17	keratin 17	Keratinization Formation of the cornified envelope Developmental Lineage of Pancreatic Ductal Cells		Pachyonychia congenita, including: Jadassohn-Lewandowsky syndrome; Jackson-Lawler syndrome ; Steatocystoma multiplex
Novel	KRT18	keratin 18	Keratinization Formation of the cornified envelope Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells
Novel	LGALS1	galectin 1	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Post-translational protein phosphorylation	Mercaptoethanol Thiodigalactoside 1,4-Dithiothreitol Artenimol OTX-008
Novel	LZTR1	leucine zipper like post translational regulator 1
Novel	MAP2K1	mitogen-activated protein kinase kinase 1	MAPK3 (ERK1) activation Frs2-mediated activation Signal transduction by L1 Uptake and function of anthrax toxins RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway MAP3K8 (TPL2)-dependent MAPK1/3 activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by MAP2K mutants Signaling by RAF1 mutants	K-252a 5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide Cobimetinib Bosutinib (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide Mirdametinib N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE Trametinib Selumetinib Pimasertib	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
Novel	MAP2K6	mitogen-activated protein kinase kinase 6	NOD1/2 Signaling Pathway Oxidative Stress Induced Senescence activated TAK1 mediates p38 MAPK activation Myogenesis PI5P Regulates TP53 Acetylation Interleukin-1 signaling PKR-mediated signaling	Fostamatinib Pimasertib
Novel	MAP3K6	mitogen-activated protein kinase kinase kinase 6		Fostamatinib
Novel	MAPK10	mitogen-activated protein kinase 10	Oxidative Stress Induced Senescence FCERI mediated MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 Activation of the AP-1 family of transcription factors	Minocycline Pyrazolanthrone Cyclohexyl-{4-[5-(3,4-Dichlorophenyl)-2-Piperidin-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine Cyclopropyl-{4-[5-(3,4-Dichlorophenyl)-2-[(1-Methyl)-Piperidin]-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine 9-(4-Hydroxyphenyl)-2,7-Phenanthroline Phosphoaminophosphonic Acid-Adenylate Ester N-(tert-butyl)-4-[5-(pyridin-2-ylamino)quinolin-3-yl]benzenesulfonamide N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide 4-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-N-ethylpiperidine-1-carboxamide (3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oxime (3E)-5-fluoro-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-1H-indole-2,3-dione 3-oxime (3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-phenyl-1H-indole-2,3-dione 3-oxime 5-bromo-N-(3-chloro-2-(4-(prop-2-ynyl)piperazin-1-yl)phenyl)furan-2-carboxamide N-cyclohexyl-4-imidazo[1,2-a]pyridin-3-yl-N-methylpyrimidin-2-amine N-{2'-[(4-FLUOROPHENYL)AMINO]-4,4'-BIPYRIDIN-2-YL}-4-METHOXYCYCLOHEXANECARBOXAMIDE 2-{4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]piperidin-1-yl}-N-methylacetamide 1-(3-bromophenyl)-7-chloro-6-methoxy-3,4-dihydroisoquinoline Fostamatinib Halicin
Novel	MAPK8	mitogen-activated protein kinase 8	Activation of BIM and translocation to mitochondria Activation of BMF and translocation to mitochondria NRAGE signals death through JNK NRAGE signals death through JNK NRIF signals cell death from the nucleus Oxidative Stress Induced Senescence FCERI mediated MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 Activation of the AP-1 family of transcription factors Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-38 signaling WNT5:FZD7-mediated leishmania damping Signaling by ALK fusions and activated point mutants	Tamoxifen Minocycline Pyrazolanthrone 6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE 2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE 5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE 2-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzamide Halicin
Novel	MLH3	mutL homolog 3	Meiotic recombination		Mismatch repair deficiency, including: Hereditary non-polyposis colorectal cancer (HNPCC); Lynch syndrome; Muir-Torre syndrome; Turcot syndrome
Novel	MSH2	mutS homolog 2	Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) Defective Mismatch Repair Associated With MSH3 Defective Mismatch Repair Associated With MSH2 Defective Mismatch Repair Associated With MSH6 TP53 Regulates Transcription of DNA Repair Genes		Ovarian cancer Mismatch repair deficiency, including: Hereditary non-polyposis colorectal cancer (HNPCC); Lynch syndrome; Muir-Torre syndrome; Turcot syndrome Colorectal cancer
Novel	MSH6	mutS homolog 6	Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) Defective Mismatch Repair Associated With MSH2 Defective Mismatch Repair Associated With MSH6		Mismatch repair deficiency, including: Hereditary non-polyposis colorectal cancer (HNPCC); Lynch syndrome; Muir-Torre syndrome; Turcot syndrome Colorectal cancer
Novel	MTOR	mechanistic target of rapamycin kinase	PIP3 activates AKT signaling Macroautophagy MTOR signalling mTORC1-mediated signalling HSF1-dependent transactivation Energy dependent regulation of mTOR by LKB1-AMPK CD28 dependent PI3K/Akt signaling VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation Regulation of PTEN gene transcription Amino acids regulate mTORC1 High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	Pimecrolimus Sirolimus Everolimus Rimiducid SF1126 XL765 Ridaforolimus Temsirolimus GSK-1059615 Fostamatinib Oleandrin
Novel	MUTYH	mutY DNA glycosylase			Familial adenomatous polyposis

Search Results for: HRAS